Idorsia (CHIX:IDIAZ) Beneish M-Score: -3.02 (As of Jun. 26, 2026)


CHIX:IDIAZ Idorsia Ltd CHIX:IDIAZ
63 GF Score
Price CHF6.02
GF Value CHF2.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Beneish M-Score?

Idorsia CHIX:IDIAZ +3.79% 63 Beneish M-Score is -3.02 as of Jun. 26, 2026. GuruFocus rates CHIX:IDIAZ with a GF Score™ of 63/100 and a GF Value™ of CHF2.88 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Idorsia ranks better than 75.21% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.02 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Idorsia's Beneish M-Score or its related term are showing as below:

CHIX:IDIAz' s Beneish M-Score Range Over the Past 10 Years
Min: -4.05   Med: -0.84   Max: 3.89
Current: -3.02

During the past 10 years, the highest Beneish M-Score of Idorsia was 3.89. The lowest was -4.05. And the median was -0.84.


Idorsia Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Idorsia's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia Beneish M-Score Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -1.30 0.21 -0.48 -1.54

Idorsia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -0.25 -0.89 -1.54 -3.02

CHIX:IDIAZ vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Idorsia's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Idorsia Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Idorsia's Beneish M-Score falls into.


CHIX:IDIAZ
63GF Score
Idorsia Ltd CHIX:IDIAZ
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idorsia Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Idorsia for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1995+0.528 * 0.8921+0.404 * 0.8719+0.892 * 1.358+0.115 * 0.9665
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6298+4.679 * -0.210897-0.327 * 1.0114
=-3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was CHF55.3 Mil.
Revenue was 57.394 + 47.972 + 41.487 + 72.241 = CHF219.1 Mil.
Gross Profit was 49.331 + 38.581 + 35.795 + 68.853 = CHF192.6 Mil.
Total Current Assets was CHF239.6 Mil.
Total Assets was CHF480.5 Mil.
Property, Plant and Equipment(Net PPE) was CHF187.1 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF16.9 Mil.
Selling, General, & Admin. Expense(SGA) was CHF220.4 Mil.
Total Current Liabilities was CHF149.7 Mil.
Long-Term Debt & Capital Lease Obligation was CHF1,312.6 Mil.
Net Income was -45.696 + -77.76 + -85.679 + -11.375 = CHF-220.5 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = CHF0.0 Mil.
Cash Flow from Operations was -26.63 + -43.326 + -13.965 + -35.262 = CHF-119.2 Mil.
Total Receivables was CHF33.9 Mil.
Revenue was 58.883 + 59.9 + 26.202 + 16.347 = CHF161.3 Mil.
Gross Profit was 56.442 + 40.006 + 14.538 + 15.509 = CHF126.5 Mil.
Total Current Assets was CHF186.4 Mil.
Total Assets was CHF456.2 Mil.
Property, Plant and Equipment(Net PPE) was CHF211.1 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF18.4 Mil.
Selling, General, & Admin. Expense(SGA) was CHF257.6 Mil.
Total Current Liabilities was CHF327.5 Mil.
Long-Term Debt & Capital Lease Obligation was CHF1,045.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(55.258 / 219.094) / (33.923 / 161.332)
=0.252211 / 0.210268
=1.1995

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(126.495 / 161.332) / (192.56 / 219.094)
=0.784066 / 0.878892
=0.8921

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (239.561 + 187.064) / 480.458) / (1 - (186.429 + 211.117) / 456.17)
=0.112045 / 0.128513
=0.8719

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=219.094 / 161.332
=1.358

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.353 / (18.353 + 211.117)) / (16.876 / (16.876 + 187.064))
=0.07998 / 0.08275
=0.9665

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(220.353 / 219.094) / (257.621 / 161.332)
=1.005746 / 1.596838
=0.6298

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1312.635 + 149.701) / 480.458) / ((1045.316 + 327.472) / 456.17)
=3.043629 / 3.009378
=1.0114

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-220.51 - 0 - -119.183) / 480.458
=-0.210897

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Idorsia has a M-score of -3.02 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.02 mean?
Idorsia (CHIX:IDIAZ) has a Beneish M-Score of -3.02 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #206 out of 831 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Idorsia's Beneish M-Score too high?
Idorsia's current Beneish M-Score is -3.02. Based on the distribution chart, Idorsia ranks #206 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Idorsia has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #206 out of 831 companies for Beneish M-Score. This places Idorsia in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Idorsia and its competitors. Idorsia's current Beneish M-Score is -3.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (CHIX:IDIAZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.88, compared to a current price of CHF6.02 — trading 109% above its estimated fair value. The current Beneish M-Score is -3.02. Idorsia's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Idorsia (CHIX:IDIAZ), the current Beneish M-Score is -3.02 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Idorsia (CHIX:IDIAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.02 is trading 109% above its estimated GF Value™ of CHF2.88. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for CHIX:IDIAZ:

  • Beneish M-Score: -3.02
  • GF Value™: CHF2.88 vs. price of CHF6.02 (109% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the CHIX:IDIAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
63GF Score

Get the complete analysis for CHIX:IDIAZ

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.02
Price
CHF2.88
GF Value